Smith L, et al. - Authors reviewed the characteristics of patients in cardiogenic shock treated with TandemHeart percutaneous ventricular assist device (pVAD) to ascertain influential predictors of survival. They retrospectively analyzed the patients referred for TandemHeart pVAD implant for refractory cardiogenic shock at the University of Virginia between September 2007 and October 2015. Findings suggested that even with TandemHeart support, mortality from refractory cardiogenic shock was high. A significant influence of patients with an exit strategy with either cardiac surgery or durable LVAD implant on survival to hospital discharge was seen.